



Date : 08.12.2017

To,
Listing Department,
Dept. of Corporate Services,
Bombay Stock Exchange Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai: 400 001.

To,
General Manager,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai: 400 051.

Dear Sir/Madam,

Ref.:- Scrip Code - 532908 Scrip ID-SHARONBIO

Sub:- Financial Results for the year ended 31st March, 2017.

Pursuant to provisions of SEBI LODR Regulations, 2015, we would like to intimate the exchange that Resolution Professional on 08 December, 2017 has considered and approved the following

- i) The Standalone Audited Financial Results of the Company for the year ended on 31st March, 2017.
- ii) Statement of Assets & Liabilities as at that date.
- iii) The Auditors Report on Standalone Financial Results for the year ended on 31st March, 2017.

Further Please note that the Company has already made necessary arrangement to publish the same in the newspaper as required under SEBI (LODR), Regulations, 2015.

Kindly find the same for your record & acknowledge the receipt for the same.

Thanking You,

Yours faithfully,
For Sharon Bio-Medicine Limited


Deepali Bhatia

Company Secretary & Compliance officer

Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.

Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships



Sharon
BIO-MEDICINE LTD.

An ISO-9001:2000
Certified Company



**Extract of Standalone unaudited financial results
for the year ended March 31, 2017**

(₹ in Lacs)

SR. NO.	PARTICULARS	Quarter ended 31/03/2017	Year ended 31/03/2017	Corresponding quarter ended 31/03/2016
		Audited	Audited	Audited
1	Total Income from Operations (net)	2,456.66	13,880.59	3,576.85
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(587.36)	(33,181.40)	(18,106.20)
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(1,948.08)	(34,551.85)	(14,380.51)
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(2,182.56)	(34,786.33)	(15,377.08)
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	(2,182.56)	(34,786.33)	(15,377.08)
6	Paid-up Equity Share Capital (Face value of ₹.2/- each)	2,378.71	2,378.71	2,378.71
7	Earnings Per Share (of ₹.2/- each) (for continuing and discontinued operations) (not annualised)			
	a) Basic (in Rs.)	(1.84)	(29.25)	(12.93)
	b) Diluted (in Rs.)	(1.84)	(29.25)	(12.93)

Notes:

- 1) The Statutory Auditors of the Company have carried out the Limited Review of the above standalone results.
- 2) The above is an extract of the detailed format of the Standalone Financial Results for the year ended March 31, 2017 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange website, www.nseindia.com and www.bseindia.com, and on the Company's website www.sharonbio.com.

For Sharon Bio-Medicine Ltd.
SD/-

Savita Gowda

Managing Director.

Dinkar Venkatasubramanian

Resolution Professional

IP Registration no. IBB/IIPA-001/

IP-P00003/2016-17/10011

Place : Mumbai.

Date : December 8, 2017

REGISTERED OFFICE & WORKS : W-34 & 34/1, MIDC, Taloja,
Dist.Raigad, Maharashtra (India).

CORP.: C-310/312, BSEL Tech Park, Opp. Vashi-Railway Station, Navi Mumbai – 400 703.

E-mail : investor_complaints@sharonbio.com, Website : www.sharonbio.com